QBiotics appoints Andrew Craig to the role of Global Investor Relations Officer

BRISBANE, 7 May 2026

QBiotics Group Limited (QBiotics) is pleased to announce the appointment of Andrew Craig as Global Investor Relations Officer.

Andrew Craig is an experienced investment banker with almost three decades in global capital markets. He began his career at SBC Warburg (UBS) in the late 1990s and went on to hold senior equity roles in London and New York, working closely with institutional investors and publiccompany leadership teams.

From 2015 to 2021, Andrew was a partner at WG Partners LLP, a specialist life sciences investment bank, where he advised more than 60 biotechnology companies. Through his career he has met with the senior management teams of over a thousand companies, engaged with several hundred professional investors, and contributed to major transactions, including Sweden’s $7.6 billion selldown of Nordea Bank AB and the IPOs of companies such as easyJet, HMV, Burberry, Campari, Carluccio’s, the Carbon Trust, and lastminute.com.

Alongside his banking career, Andrew is the founder of Plain English Finance and a best-selling author. His first book, How to Own the World, remains one of the UK’s most successful personal finance titles. His third book, Our Future is Biotech, was published globally in 2024, and examines how biotechnology can help address major global challenges in health, sustainability and economic development. Andrew has been a regular commentator on finance and science in the UK. He has appeared in numerous national and specialist financial publications, including; The Telegraph, The Financial Times, City A.M., Shares and MoneyWeek, and been interviewed on Sky TV and Bloomberg Radio.

Interim CEO and Managing Director for QBiotics, Ebru Davidson commented, “Andrew has been closely connected to QBiotics for many years, and his appointment brings immediate depth to our senior team. His experience and global network will expand our international investor reach and sharpen our engagement with institutions aligned to our long-term vision. He will play a pivotal role as we deepen relationships with long-term global capital in regions outside of Australia.”

Andrew Craig commented, “I have had the privilege of working closely with the QBiotics team since 2017. My strong belief is that QBiotics is a highly differentiated and exciting biotech. The company has a unique platform technology capable of addressing a number of extremely large end-markets, and of making a material impact on patient outcomes. I am thrilled to be joining the team and to have the chance to take the equity story to as wide an investor audience as possible.”

Andy has been engaged in a part time capacity for an initial term of 18 months.Under this newly created role, Andrew will focus on expanding QBiotics’ investor relationships outside of Australia.

—ends—
 

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS

QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.

QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. In a Phase II soft tissue sarcoma study the drug delivered an injected tumour Objective Response Rate (ORR) of 80%, with no serious Adverse Events, and translational research validating immunological responses. A Phase II study in head & neck cancer is soon to be reported and impressive safety and efficacy outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I/IIa safety study and efficacy reported for nine different tumour types.

QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human clinical Phase I/IIa study treating Venous Leg Ulcers.

Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of the drug secured for both programmes.

QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complimented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, and translational drug development.

QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.

For more, head to: QBiotics.com or LinkedIn